A month has gone by since the last earnings report for Luminex (
LMNX Quick Quote LMNX - Free Report) . Shares have added about 13.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Luminex due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Luminex Loss Wider Than Estimates in Q3, Assay Revenues Down
Luminex reported third-quarter 2019 loss of 12 cents per share, significantly wider than the Zacks Consensus Estimate of 3 cents per share. Notably, the company reported earnings of 4 cents per share in the year-ago quarter.
Revenues in Detail
Revenues came in at $78.7 million, missing the Zacks Consensus Estimate by 3.9%. However, the top line improved 8.6% on a year-over-year basis.
Total sample-to-answer franchise revenues grew 27% from the prior-year quarter.
Segmental Analysis System Sales
Revenues at this segment totaled $15.2 million, surging 52% from the year-ago quarter.
This segment accounted for $13.4 million of revenues, up 14.9% year over year.
Royalty revenues totaled $12.9 million, up 7.5% on a year-over-year basis.
This segment reported revenues worth $29.5 million, down 12.7% on a year-over-year basis.
Revenues in the segment amounted to $5.3 million, up 77.4% from the year-ago quarter.
Other revenues came in at $2.3 million, up 16.2% from a year ago.
Per management, this Texas-based company placed 31 sample-to-answer molecular systems under contract during the third quarter. Active sample-to-answer customers totaled 650 in the quarter under review.
As of Sep 30, 2019, cash and cash equivalents totaled $66.1 million, down 4.4% sequentially.
Cash flow from operating activities for the three months ended Sep 30, 2019, came in at $9.4 million, down 37.7% from the year-ago quarter.
Gross profit in the reported quarter was $41.8 million, down 5.5% year over year. Gross margin was 53.2%, contracting 790 bps.
Research and development expenses totaled $13.3 million, up 10.6% year over year. Selling, general and administrative expenses in the third quarter were $31.4 million, up 19.4% year over year. Total operating expenses amounted to $47.6 million, up 17.4% from the year-ago reported figure.
The company incurred operating loss of $5.7 million, against the year-ago quarter’s operating income of $3.8 million.
The company revised 2019 revenue outlook, which is now estimated to range between $334 and $337 million (down from the previously guided range of $337-$343 million).
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -94.64% due to these changes.
Currently, Luminex has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Luminex has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.